

## Сведения об официальном оппоненте

**Деев Сергей Михайлович**, доктор биологических наук, специальность - Молекулярная биология (03.00.03), профессор, академик РАН, главный научный сотрудник, зав. лабораторией молекулярной иммунологии, Государственный научный центр Федеральное государственное учреждение науки Институт биоорганической химии имени академиков М.М. Шемякина и Ю.А. Овчинникова РАН.

Список основных публикаций по теме диссертации за последние 5 лет:

1. Kalinovskiy, D. V., Kholodenko, I. V., Kibardin, A. V., Doronin, I. I., Svirshchevskaya, E. V., Ryazantsev, D. Y., Konovalova, M. V., Rozov, F. N., Larin, S. S., Deyev, S. M., & Kholodenko, R. V. (2023). Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells. *International journal of molecular sciences*, 24(2), 1239
2. Stepanov AV, Kalinin RS, Shipunova VO, Zhang D, Xie J, Rubtsov YP, Ukrainskaya VM, Schulga A, Konovalova EV, Volkov DV, Yaroshevich IA, Moysenovich AM, Belogurov AA Jr, Zhang H, Telegin GB, Chernov AS, Maschan MA, Terekhov SS, Wu P, Deyev SM, Lerner RA, Gabibov AG, Altman S. Switchable targeting of solid tumors by BsCAR T cells. *Proc Natl Acad Sci U S A*. 2022 Nov 16;119(46):e2210562119. doi: 10.1073/pnas.2210562119. Epub 2022 Nov 7. PMID: 36343224.
3. Frolova, A. Y., Pakhomov, A. A., Kakuev, D. L., Sungurova, A. S., Deyev, S. M., & Martynov, V. I. (2022). Cancer cells targeting with genetically engineered constructs based on a pH-dependent membrane insertion peptide and fluorescent protein. *Biochemical and Biophysical Research Communications*, 612, 141-146. IF 3.322
4. Xu, T., Liu, Y., Schulga, A., Konovalova, E., Deyev, S. M., Tolmachev, V., & Vorobyeva, A. (2022). Epithelial cell adhesion molecule-targeting designed ankyrin repeat protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer cells. *Oncology Reports*, 47(5), 1-10.
5. Bragina, O., Chernov, V., Schulga, A., Konovalova, E., Garbukov, E., Vorobyeva, A., Orlova, A., Tashireva, L., Sørensen, J., Zelchan, R., Medvedeva, A., Deyev, S., & Tolmachev, V. (2022). Phase I Trial of <sup>99m</sup>Tc-(HE)<sub>3</sub>-G3, a DARPIn-Based Probe for Imaging of HER2 Expression in Breast Cancer. *Journal of Nuclear Medicine*, 63(4), 528-535.
6. Shipunova, V. O., & Deyev, S. M. (2022). Artificial Scaffold Polypeptides As an Efficient Tool for the Targeted Delivery of Nanostructures In Vitro and In Vivo. *Acta Naturae*, 14(1), 54.

7. Shramova, E. I., Chumakov, S. P., Shipunova, V. O., Ryabova, A. V., Telegin, G. B., Kabashin, A. V., Deyev, S. M., & Proshkina, G. M. (2022). Genetically encoded BRET-activated photodynamic therapy for the treatment of deep-seated tumors. *Light: Science & Applications*, 11(1), 1-13.
8. Kalinovskiy, D. V., Kibardin, A. V., Kholodenko, I. V., Svirshchevskaya, E. V., Doronin, I. I., Konovalova, M. V., Grechikhina, M. V., Rozov, F. N., Larin, S. S., Deyev, S. M., & Kholodenko, R. V. (2022). Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors. *Journal for immunotherapy of cancer*, 10(6).
9. Shilova, O., Kotelnikova, P., Proshkina, G., Shramova, E., & Deyev, S. (2021). Barnase-Barstar Pair: Contemporary Application in Cancer Research and Nanotechnology. *Molecules*, 26(22), 6785.
10. Xu, T., Vorobyeva, A., Schulga, A., Konovalova, E., Vorontsova, O., Ding, H., ... & Deyev, S. M. (2021). Imaging-guided therapy simultaneously targeting HER2 and EpCAM with trastuzumab and EpCAM-directed toxin provides additive effect in ovarian cancer model. *Cancers*, 13(16), 3939.
11. Shilova, O., Shramova, E., Proshkina, G., & Deyev, S. (2021). Natural and designed toxins for precise therapy: Modern approaches in experimental oncology. *International Journal of Molecular Sciences*, 22(9), 4975.
12. Shramova, E. I., Shilova, M. V., Ryabova, A. V., Dzhililova, D. S., Zolotova, N. A., Telegin, G. B., Deyev, S. M., & Proshkina, G. M. (2021). Barnase\* Barstar-guided two-step targeting approach for drug delivery to tumor cells in vivo. *Journal of Controlled Release*, 340, 200-208.
13. Artykov, A. A., Belov, D. A., Shipunova, V. O., Trushina, D. B., Deyev, S. M., Dolgikh, D. A., ... & Gasparian, M. E. (2020). Chemotherapeutic agents sensitize resistant cancer cells to the DR5-specific variant DR5-B more efficiently than to TRAIL by modulating the surface expression of death and decoy receptors. *Cancers*, 12(5), 1129.
14. Deyev, S. M., Vorobyeva, A., Schulga, A., Abouzayed, A., Günther, T., Garousi, J., ... & Tolmachev, V. (2020). Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPIn Ec1. *International journal of biological macromolecules*, 145, 216-225.